FDA Nixes Innovator Industry-Backed Changes To Citizen Petition Rule

Agency rejects PhRMA requests to ease certification process and limit rule's application; separately, law firm Hyman, Phelps & McNamara objects to FDA practice of delaying ANDA approval announcements until it issues a petition decision.

StacksOfPapers_1200x675

FDA’s final rule on citizen petitions makes only minor revisions to its proposed regulation, most notably shortening the agency’s response time from 180 days to 150 days.

The document instead is largely devoted to rejecting suggestions by the Pharmaceutical Research and Manufacturers of America to alter the...

More from Legal & IP

More from Pink Sheet

Recent And Upcoming FDA Advisory Committee Meetings

 
• By 

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK-Wide Strategy Needed To Move Clinical Trial Diversity Plans To Next Stage

 
• By 

The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.

Blenrep’s Comeback Continues As England Becomes First To Fund Drug

 

Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.